May 03, 2018 06:00 am UTC| Business
Waltham, MA, May 03, 2018 -- CallMiner, the leading platform provider of award-winning speech and customer engagement analytics, announced today that Veridian Credit Union has selected CallMiner’s Eureka platform and...
Nicox announces the presentation of scientific data for NCX 667 at ARVO 2018
May 03, 2018 05:30 am UTC| Business
Press Release Nicox announces the presentation of scientific data for NCX 667 at ARVO 2018 NCX 667 demonstrates robust, dose-dependent lowering of intraocular pressure in various normotensive and...
World Health Organization Grants Name ‘Seliforant’ to Sensorion’s SENS-111 Treatment
May 03, 2018 05:30 am UTC| Business
Seliforant (formerly SENS-111) is a first-in-class histamine H4 receptor antagonist candidate selected for the treatment of vertigo of vestibular origin, in development to treat acute unilateral vestibulopathy (AUV), a...
Targovax ASA: First quarter 2018 results
May 03, 2018 05:03 am UTC| Business
Oslo, Norway, 3 May 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its first quarter 2018 results. A meeting for...
BOURBON: 1st Quarter 2018 Financial information
May 03, 2018 05:03 am UTC| Business
Marseilles, May 3, 2018 BOURBON 1st Quarter 2018 financial information Adjusted revenue for the 1st quarter 2018 amounted to €171 million (consolidated revenue was €157.6 million), down 13.2% compared to...
May 03, 2018 05:01 am UTC| Business
REGULATED INFORMATION GHENT, Belgium, 3 May 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major...
Celyad Successfully Administers CYAD-01 in First Patients in SHRINK and LINK Trials
May 03, 2018 05:00 am UTC| Business
Celyad achieves important milestone in CYAD-01 treatment evaluation of metastatic colorectal cancer: No toxicity observed to date in first patient enrolled in the SHRINK1 trial (concurrent administration of CYAD-01 ...